Cipher Pharmaceuticals Inc. (FRA:PHE)

Germany · Delayed Price · Currency is EUR

8.95

0.00 (0.00%)

Last updated: Dec 5, 2025, 8:04 AM CET

-15.57% (1Y)

Market Cap	229.63M
Revenue (ttm)	42.66M
Net Income (ttm)	14.80M
Shares Out	n/a
EPS (ttm)	0.57
PE Ratio	15.52
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	50
Open	8.95
Previous Close	8.95
Day's Range	8.95 - 8.95
52-Week Range	6.85 - 10.80
Beta	n/a
RSI	54.53
Earnings Date	Mar 19, 2026

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients; Vaniqa... [Read more]

Industry Pharmaceutical Preparations

Founded 2000

Employees 5

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol PHE

Full Company Profile

Financial Performance

In 2024, Cipher Pharmaceuticals's revenue was $33.36 million, an increase of 57.66% compared to the previous year's $21.16 million. Earnings were $11.55 million, a decrease of -43.36%.

Financial numbers in USD Financial Statements

News

There is no news available yet.